Also known as: Ubrelvy
Ubrelvy (ubrogepant) is an oral CGRP receptor antagonist approved for the acute treatment of migraine attacks with or without aura in adults. It is used as-needed and is not indicated for preventive migraine treatment. Initial U.S. approval was in 2019 with label updates through 2025.
AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
AbbVie projects 43-45% earnings growth in 2026 as newer immunology drugs Skyrizi and Rinvoq offset declining Humira sales, while maintaining its 54-year dividend increase streak as a Dividend King.
